Actinium director gets 62.8K RSUs, 94.2K options
ATNM director Richard I. Steinhart received new restricted stock units and stock options as equity compensation, increasing his direct holdings and future vested rights.
Rhea-AI Filing Summary
Actinium Pharmaceuticals, Inc. (ATNM) reported that director Richard I. Steinhart received equity awards on September 2, 2026. He was granted 62,800 shares of Common Stock in the form of restricted stock units that vest in three equal annual installments over three years, resulting in 63,116 Common shares held directly after the grant. He also received a stock option for 94,200 shares of Common Stock at an exercise price of $1.00 per share, vesting in fifty equal monthly tranches and expiring on September 2, 2036. No Rule 10b5-1 trading plan is reported for these awards.
Positive
- None.
Negative
- None.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to Buy) F2 | 94,200 | $0.00 | $0.00 |
| Grant/Award | Common Stock F1 | 62,800 | $0.00 | $0.00 |
Footnotes (2)
- F1. Represents a grant of restricted stock units ("RSUs"). The RSUs vest as follows: 1/3 on the first anniversary of the date of grant, 1/3 on the second anniversary of the date of grant and 1/3 on the third anniversary of the date of grant.
- F2. The stock options vest and become exercisable in fifty equal monthly tranches beginning on the date of grant.
Key Figures
Key Terms
restricted stock units ("RSUs") financial
vest financial
stock options financial
exercisable financial
FAQ
What equity awards did ATNM grant to director Richard I. Steinhart on September 2, 2026?
How do the new restricted stock units for ATNM’s director vest?
What is the vesting schedule of the new ATNM stock options granted to the director?
Were the ATNM director’s equity awards made under a Rule 10b5-1 trading plan?
AI-generated analysis. How Rhea-AI works. Not financial advice.